11:36 AM EDT, 04/03/2024 (MT Newswires) -- LENZ Therapeutics ( LENZ ) said Wednesday that a phase 3 trial of LNZ100 met its primary and key secondary endpoints in patients with presbyopia, the loss of near vision associated with aging.

LNZ100 is an eye drop with 1.75% aceclidine formulation, the company said.

Topline data show that 71% of participants dosed with LNZ100 achieved three-lines or greater improvement at three hours, the company said, adding that the treatment also resulted in rapid onset and long duration.

LENZ said it has picked LNZ100 as its lead product candidate, and plans to submit a new drug application in mid-2024.

Another aceclidine formulation, LNZ101, showed similar results, including achieving primary and secondary endpoints, it said.

The stock was down more than 4% in recent trading.

Price: 20.15, Change: -0.86, Percent Change: -4.10